El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Ligand Pharmaceuticals Inc
Cerrado
SectorSanidad
188.14 -0.71
Resumen
Variación precio
24h
Mínimo
185.04
Máximo
191.6
Ingresos | 112M 117M |
|---|---|
Ventas | 115M |
P/B Media del Sector | 86.354 88.032 |
Margen de beneficios | 101.569 |
Empleados | 68 |
EBITDA | 87M 149M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +28.02% upside |
Capitalización Mercado | -278M 3.8B |
|---|---|
Apertura anterior | 188.85 |
Cierre anterior | 188.14 |
Noticias sobre sentimiento de mercado
By Acuity
20%
80%
36 / 374 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Strong Bearish Evidence
Ligand Pharmaceuticals Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Ligand Pharmaceuticals Inc previsión
Precio Objetivo
By TipRanks
28.02% repunte
Estimación a 12 Meses
Media 243.5 USD 28.02%
Máximo 275 USD
Mínimo 220 USD
De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ligand Pharmaceuticals Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
36 / 374 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
Live chat